novo nordisk glp-1 drug Novo, Lilly weight-loss drugs should be first option obesity treatments, European doctors say The FDA has approved the

While it may help improve the appearance of dull or pale skin caused by a deficiency, it is not a direct skin whitening solution

Continuous and consistent use will result into gradual skin lightening until you reach the skin tone you desire

Category 3 These substances did not have enough supporting information submitted for review

Since control of diabetes and obesity are significant health outcome risk factors, it is conceivable that the shortages and high cost of GLP1 agonists will exacerbate existing health disparities. David Cutler, MD His perspective echoed what Ma told us, namely that [o]ne of the biggest bottlenecks with GLP-1RA access is cost and insurance. Even if a doctor prescribes [this type of drug], patients cannot obtain it if their insurance does not cover it, which could worsen disparities, especially for those with public insurance or in underserved populations, he also emphasized

All authors gave final approval and agreed to be accountable for all aspects of the work